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Abstract: Two α-synuclein ligands, 3-methoxy-7-nitro-10H-phenothiazine (2a,  
Ki = 32.1 ± 1.3 nM) and 3-(2-fluoroethoxy)-7-nitro-10H-phenothiazine (2b,  
Ki = 49.0 ± 4.9 nM), were radiolabeled as potential PET imaging agents by respectively 
introducing 11C and 18F. The syntheses of [11C]2a and [18F]2b were accomplished in a good 
yield with high specific activity. Ex vivo biodistribution studies in rats revealed that both 
[11C]2a and [18F]2b crossed the blood-brain barrier (BBB) and demonstrated good brain 
uptake 5 min post-injection. MicroPET imaging of [11C]2a in a non-human primate (NHP) 
confirmed that the tracer was able to cross the BBB with rapid washout kinetics from brain 
regions of a healthy macaque. The initial studies suggested that further structural 
optimization of [11C]2a and [18F]2b is necessary in order to identify a highly specific 
positron emission tomography (PET) radioligand for in vivo imaging of α-synuclein 
aggregation in the central nervous system (CNS). 
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Abbreviations: α-syn, α-synuclein; BBB, blood-brain barrier; calcd., calculated; CNS, central 
nervous system; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM, dichloromethane; DMF,  
N,N-dimethylformamide; DMSO, dimethyl sulfoxide; EOB, end of bombardment; [18F]FEOTs, 
[18F]fluoroethyltosylate; HPLC, high performance liquid chromatography; HRMS, high resolution 
mass spectrometry; LBs, Lewy bodies; LNs, Lewy neuritis; NHP, non-human primate; PD, 
Parkinson’s disease; PET, positron emission tomography; QC, quality control; RCY, radiochemical 
yield; SAR, structure-activity relationship; SD, Sprague Dawley; SUV, standardized uptake value; 
TAC, time-activity curve; VMAT2, vesicular monoamine transporter type 2. 
1. Introduction 
Although Parkinson’s disease (PD) is a degenerative neurological disorder characterized by motor 
symptoms, it is also known to be closely associated with dementia [1]. The primary neuropathologic 
change in PD, the degeneration of dopaminergic neurons, occurs in the substantia nigra, accompanied 
by Lewy bodies (LB) and Lewy neurites (LN). To date, the pathogenic mechanism of PD is not fully 
understood [2]. The diagnosis of PD is primarily based on the clinical symptoms, such as resting 
tremor, bradykinesia and rigidity. Because the current treatment for PD is to minimize the disease 
symptoms in the patients [1,3], a method of diagnosing PD at a very early stage would greatly help 
physicians to design the therapy accordingly.  
α-Synuclein (α-syn) is a presynaptic terminal protein that consists of 140 amino acids; the 
aggregation of α-syn is considered the pathological hallmark of PD. α-Syn plays an important role in 
the central nervous system (CNS) in synaptic vesicle recycling; it also regulates the synthesis, storage 
and release of neurotransmitters [4]. It is specifically upregulated in a discrete population of 
presynaptic terminals of the brain during acquisition-related synaptic rearrangement [5]. α-Syn 
naturally exists in a highly soluble, unfolded state [6,7]. However, in PD brains, insoluble aggregation 
of misfolded fibrillar α-syn occurs in LB and LN, which may cause synaptic dysfunction and neuronal 
cell death [8–11]. Positron emission tomography (PET) is a non-invasive imaging modality that can 
provide the functional information of a living subject at the molecular and cellular level. Current 
diagnostic PET radioligands for PD target either the dopaminergic system (pre-synaptic and  
post-synaptic dopamine activity) or vesicular monoamine transporter type 2 (VMAT2) [12,13]. 
Unfortunately, such imaging strategies have difficulty in distinguishing PD from other parkinsonian 
syndromes that also result in the degeneration of nigrostriatal projections [14,15]. In addition, 
dopaminergic medications used for symptomatic treatment may alter striatal uptake of these agents, 
limiting their reliability for measuring disease progression [16]. In contrast, α-syn is a valuable 
imaging target for PD, because fibrillar α-syn deposition in LB and LN distinguishes PD from other 
disorders and is the defining feature for post-mortem pathologic diagnosis. Thus, a small molecular 
PET radiotracer with high affinity and selectivity to fibrillar α-syn protein could be used to quantify 
the level of α-syn aggregation non-invasively. This will not only improve the diagnostic accuracy of 
PD, but also provide a tool to improve the understanding of disease progression and monitor the 
therapeutic efficacy in clinical trials. 
Our group previously reported the syntheses of a class of tricyclic analogues and their in vitro 
binding affinities towards α-syn fibrils; several lead compounds were identified with moderate 
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affinities for α-syn fibrils (Ki < 70 nM) (Figure 1, 2a, 2b) [17]. Compounds 2a and 2b also displayed 
favorable binding selectivity to α-synuclein aggregation compared to Aβ and tau protein: for 2a,  
Ki-α-syn/Ki-Aβ > 3-fold and Ki-α-syn/Ki-tau > 4-fold; for 2b, Ki-α-syn/Ki-Aβ = 2.1-fold and  
Ki-α-syn/Ki-tau = 2.5-fold [18]. The radioiodinated ligand, [125I]1, was synthesized to establish a 
methodology for screening the α-syn fibril binding affinity of new ligands using a competition binding 
assay [18]. The affinities for 2a and 2b were determined using this [125I]1 assay, and the resulting Ki 
values (66.2 nM for 2a, 19.9 nM for 2b) were in the same range as the values obtained by the 
Thioflavin T assay. The 125I competition assay further confirmed the previously determined in vitro 
potency of 2a and 2b, which were developed as potential PET radioligands to be radiolabeled by 11C 
or 18F. In the current manuscript, we report the radiosyntheses of [11C]2a and [18F]2b and their 
validation in animal studies to determine whether [11C]2a and [18F]2b can penetrate the blood-brain 
barrier (BBB), have sufficient brain uptake and fast washout from the brain. Results of ex vivo 
biodistribution of [11C]2a and [18F]2b in Sprague-Dawley rats and microPET CNS imaging in a 
cynomolgus macaque of [11C]2a suggest that further structure-activity relationship (SAR) study is 
necessary for identifying a highly specific PET radioligand targeting α-syn aggregation. 
Figure 1. Potent tricyclic aromatic ring analogues. a Thioflavin T fluorescence assay; b 125I 












Ki- -syn = 32.1 ± 1.3 nMa
Ki- -syn = 66.2 nM (49.2-89.1 nM)b,c
Ki-A = 110 nM (94.7-127 nM)c






Ki- -syn = 49.0 ± 4.9 nMa
Ki- -syn = 19.9 nM (11.7-20.6 nM)b,c
Ki-A = 103 nM (83.6-128 nM)c
Ki-tau = 125 nM (97.7-160 nM)c
I
 
2. Experimental Section  
2.1. Chemistry 
2.1.1. General 
All reagents and chemicals were purchased from Sigma-Aldrich Corporation (Milwaukee, WI, 
USA) and used without further purification, unless otherwise stated. The melting points of all 
intermediates and final compounds were determined on a Haake-Buchler melting point apparatus and 
are uncorrected. 1H and 13C NMR spectra were recorded on a Varian-400 MHz spectrometer (Varian 
Inc. Palo Alto, CA, USA), which is maintained by the Chemistry Department of Washington 
University in St. Louis, MO, USA. Spectra are referenced to the deuterium lock frequency of the 
spectrometer. The chemical shifts (in parts per million) of residual solvents were found to be at 7.26 
for CHCl3 and at 2.50 for dimethyl sulfoxide (DMSO).  
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Compound 4, the precursor for radiolabeling [11C]2a and [18F]2b, was synthesized according to 
Scheme 1 and the previously reported procedure [17] with necessary modification. 
Scheme 1. Synthesis of phenol Precursor 4. rt, room temperature. Reagents and conditions: 
a AcCl, DCM, rt, overnight; b BBr3 in DCM (1.0 M), DCM, −78 °C–rt, overnight. 
 
2.1.2. 1-(3-Methoxy-7-nitro-10H-phenothiazin-10-yl)ethanone (3) 
Acetyl chloride (360 mg, 4.59 mmol) was added into the solution of Compound 2a (420 mg,  
1.53 mmol) in dichloromethane (10 mL). The reaction mixture was stirred overnight at room 
temperature (rt). The solvent and excess acetyl chloride was removed under reduced pressure. The 
residue was dissolved in ethyl acetate and washed with water and saturated sodium chloride solution. 
The organic extract was dried over anhydrous Na2SO4 and purified by silica gel column 
chromatography using ethyl acetate/hexane (1/2, v/v) as the mobile phase to yield Compound 3 as a 
yellow solid (267 mg, 55%). 1H NMR (CDCl3): δ 2.23 (s, 3H), 3.83 (s, 3H), 6.90 (d, J = 9.0 Hz, 1H), 
6.98 (s, 1H), 7.32 (d, J = 8.7 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.7 Hz, 1H), 8.29 (s, 1H). 
13C NMR (CDCl3): δ 22.9, 55.7, 112.7, 114.0, 122.0, 122.9, 127.4, 127.9, 130.7, 133.2, 134.3, 144.7, 
145.6, 158.5, 169.2. Combustion elemental analysis (anal.) calculated (calcd.) for C15H12N2O4S: C, 
56.95; H, 3.82; N, 8.86. Found: C, 56.72; H, 3.89; N, 8.70. mp 155.9–156.8 °C. 
2.1.3. 1-(3-Hydroxy-7-nitro-10H-phenothiazin-10-yl)ethanone (4) 
A solution of BBr3 in dichloromethane (1.0 M, 4.2 mL) was added dropwise to a solution of 
Compound 3 (267.3 mg, 0.84 mmol) in dichloromethane (15 mL) at −78 °C. The reaction solution was 
stirred overnight at rt. The solvent was removed under reduced pressure. The residue was partitioned 
between ethyl acetate and water. The organic extract was dried over anhydrous Na2SO4 and purified by 
silica gel column chromatography using ethyl acetate/CH2Cl2 (1/10, v/v) as the mobile phase to yield 
Compound 4 as a yellow solid (207.4 mg, 81%). 1H NMR (DMSO-d6): δ 2.15 (s, 3H), 6.82 (d,  
J = 9.0 Hz, 1H), 6.93 (s, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 9.0 Hz, 1H), 8.22 (d, J = 9.0 Hz, 
1H), 8.39 (s, 1H), 10.00 (br s, 1H). 13C NMR (DMSO-d6): δ 23.0, 114.3, 115.3, 122.6, 123.2, 128.4, 
128.5, 129.3, 132.3, 134.2, 145.1, 145.6, 156.7, 169.1. High resolution mass spectrometry (HRMS, 
ESI): m/z calcd. for C14H10N2O4S [M + 1] 303.0440. Found: 303.0435. Purity: 98% (HPLC 
confirmed). mp 202.3–205.1 °C. 
  




2.2.1. Radiosynthesis of [11C]2a 
2.2.1.1. Production of [11C]CH3I 
Briefly, [11C]CH3I was produced from [11C]CO2 using a GE PETtrace MeI Microlab (GE 
Healthcare, Fairfield, CT, USA). Up to 51.8 GBq of [11C]CO2 is produced from Washington 
University’s Japan Steel Works BC-16/8 cyclotron by irradiating a gas target of 0.2% O2 in N2 for  
15–30 min with a 40 µA beam of 16 MeV protons. The GE PETtrace MeI Microlab coverts the 
[11C]CO2 to [11C]CH4 using a nickel catalyst (Shimalite-Ni, Shimadzu, Japan P.N.221-27719) in the 
presence of hydrogen gas at 360 °C; it is further converted to [11C]CH3I by reacting with iodine held in 
a column in the gas phase at 690 °C. Approximately 12 min after the end of bombardment (EOB), 
several hundred millicuries of [11C]CH3I was delivered as a gas to the hot cell, where the 
radiosynthesis was accomplished. 
Scheme 2. Synthesis of [11C]2a and [18F]2b. DMF, N,N-dimethylformamide;  
[18F]FEOTs, [18F]fluoroethyltosylate; DMSO, dimethyl sulfoxide; DBU,  
1,8-diazabicyclo[5.4.0]undec-7-ene. Reagents and conditions: a [11C]CH3I/DMF, NaOH, 
90 °C, 5 min; b DBU, 7 min; c [18F]F−, Kryptofix 2.2.2, K2CO3, CH3CN, 110 °C, 10 min;  
d [18F]FEOTs, Cs2CO3, DMSO, 90 °C, 15 min; e DBU, 15 min. 
 
2.2.1.2. Radiosynthesis of [11C]2a  
Approximately 1.2 mg of Precursor 4 was placed in the reaction vessel, and 0.20 mL of DMF was 
added, followed by 3.0 µL of 5 N NaOH. The mixture was thoroughly mixed on a vortex for 30 s. A 
stream of [11C]CH3I in helium was bubbled for 3 min into the reaction vessel. The sealed vessel was 
heated at 90 °C for 5 min, at which point the vessel was removed from heat and  
20 µL 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 50 µL DMF was added via syringe. The reaction 
mixture was heated at 90 °C for 7 min (Scheme 2); then, the reaction was quenched by adding 1.7 mL 
of the HPLC mobile phase, which was composed of acetonitrile/0.1 M ammonium formate buffer 
(60/40, v/v) and pH = 4.5. The diluted solution was purified by high performance liquid 
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chromatography (HPLC) by injection on a Phenomenex Luna C18 reverse phase column  
(9.4 × 250 mm) using the mobile phase described above. The radiolabeled product was eluted using a 
flow rate of 4.0 mL/min, and the UV wavelength was set as 254 nm. Under these conditions, the 
retention time of Precursor 4 was ~7 min; the retention time of [11C]2a was ~16 min. [11C]2a was 
collected in a vial containing 50 mL Milli-Q water, which was then passed through a Sep-Pak Plus  
C18  cartridge (Waters, Milford, MA, USA). The trapped product was eluted with ethanol (0.6 mL) 
followed by 5.4 mL 0.9% saline. After sterile filtration, the final product was ready for quality control 
(QC) analysis and animal studies. QC was performed on a Phenomenex Prodigy C18 reverse phase 
analytic HPLC column (250 mm × 4.6 mm, 5 µA) and UV detection at a 254 nm wavelength. The 
mobile phase was acetonitrile/0.1 M ammonium formate buffer (80/20, v/v) using a 1.5 mL/min flow 
rate. Under these conditions, the retention time of [11C]2a was 4.82 min. The radioactive dose was 
authenticated by co-injection with the cold standard Compound 2a. Radiochemical purity was >99%; 
the chemical purity was >95%; the labeling yield was 35%–45% (n = 4, decay corrected to EOB), and 
the specific activity was >363 GBq/µmol (decay corrected to EOB, n = 4). 
2.2.2. Radiosynthesis of [18F]2b 
2.2.2.1. Production of [18F]fluoride 
[18F]Fluoride is produced by a 18O(p, n)18F reaction through proton irradiation of enriched 18O water 
(95%) using Washington University’s RDS-111 cyclotron (Siemens/CTI Molecular Imaging, 
Knoxville, TN, USA). [18F]Fluoride is first passed through an ion-exchange resin and then eluted with  
0.02 M potassium carbonate (K2CO3) solution.  
2.2.2.2. 2-[18F]Fluoroethyltosylate 
A sample of approximately 5.55 GBq [18F]/fluoride was added to a reaction vessel containing 
Kryptofix 222 (6.5–7.0 mg). The syringe was washed with 2 × 0.4 mL of ethanol. The resulting 
solution was evaporated under nitrogen flow with a bath temperature of 110 °C. Acetonitrile  
(3 × 1.0 mL) was added to the mixture, and water was azeotropically removed by evaporation. After 
all the water was removed, 5.0–5.5 mg of 1,2-ethylene ditosylate was dissolved in acetonitrile  
(200 μL), and the solution was transferred into the reaction vessel containing [18F]fluoride/Kryptofix 
222/K2CO3. The reaction vessel was capped and the reaction mixture briefly mixed and then subjected 
to heating in an oil bath that was preheated to 110 °C for 10 min (Scheme 2).  
After heating for 10 min, the reaction mixture was diluted with 3.0 mL of the HPLC mobile phase 
(50/50 acetonitrile/0.1 M ammonium formate buffer, pH = 6.5) and passed through an alumina neutral 
Sep-Pak Plus cartridge (Waters Corporation, Milford, MA, USA). The crude product was then loaded 
onto an Agilent SB-C18 semi-preparative HPLC column (250 mm × 10 mm) with a UV detector set at 
254 nm. The HPLC system used a 5 mL injection loop. At a 4.0 mL/min flow rate, the retention time 
of the product was 9.5–10 min. The retention time of the precursor was 23–24 min. The radioactivity 
peak observed on HPLC was collected and diluted with 50 mL sterile water and the diluted collection 
went through a C-18 Sep-Pak Plus cartridge to trap the 2-[18F]fluoroethyl tosylate on the Sep-Pak. The 
trapped product was eluted with diethyl ether (2.5 mL). 
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2.2.2.3. Radiosynthesis of [18F]2b 
The eluted solution formed two phases: the top ether phase was transferred out, and the bottom 
aqueous phase was extracted with another 1-mL aliquot of ether. The combined ether extracts were 
passed through a set of two sodium sulfate Sep-Pak Plus dry cartridges into a reaction vessel. After 
ether was evaporated with a nitrogen stream at 25 °C, 1.0 mg of Precursor 4 was dissolved in 200 µL 
DMSO and was transferred to a vial containing 1–2 mg Cs2CO3. After vortexing for 1 min, the Cs2CO3 
saturated solution was added to the reaction vessel containing the dried radioactive [18F]/F−. The tube 
was capped and briefly vortexed and then kept at 90 °C for 15 min. Ten microliters of  
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 50 µL DMSO was added via syringe. The reaction 
mixture was heated at 90 °C for 15 min. The mixture was subsequently diluted with 3 mL of the HPLC 
mobile phase (50/50 acetonitrile/0.1 M formate buffer, pH = 4.5) and purified using a Semi-Prep 
HPLC system for purification. The HPLC system contains a 5-mL injection loop, an Agilent SB C-18 
column, a UV detector at 254 nm and a radioactivity detector. At a 4.0 mL/min flow rate, the retention 
time of the product was 19–21 min, whereas the retention time of the precursor was 8–9 min. After the 
HPLC collection and being diluted with 50 mL sterile water, the product was trapped on a C18  
Sep-Pak Plus cartridge. The product was eluted with ethanol (0.6 mL) followed by 5.4 mL 0.9% saline. 
After sterile filtration, the final product was ready for quality control (QC) analysis and animal studies. 
An aliquot was assayed by analytical HPLC (Grace Altima C18 column, 250 × 4.6 mm), UV at  
276 nm, mobile phase of acetonitrile/0.1 M ammonium formate buffer (71/29, v/v), pH = 4.5. Under 
these conditions, the retention time for [18F]2b was approximately 4.9 min at a flow rate of  
1.5 mL/min. The sample was authenticated by co-injecting with the cold standard 2b solution. The 
radiochemical purity was >98%; the chemical purity was >95%; the labeling yield was 55%–65%  
(n = 4, decay corrected), and the specific activity was >200 GBq/µmol (decay corrected to EOB, n = 4).  
2.3. Biodistribution Studies 
All animal experiments were conducted in compliance with the Guidelines for the Care and Use of 
Research Animals under protocols approved by Washington University’s Animal Studies Committee. 
For the biodistribution studies, 11.1–13.0 MBq of [11C]2a in 200–250 µL or 1.67–1.85 MBq of [18F]2b 
in 200–250 µL of saline containing 10% ethanol was injected via the tail vein into mature male 
Sprague-Dawley rats (175–240 g) under 2%–3% isoflurane/oxygen anesthesia. Group of rats (n = 4) 
were used for each time point. At 5, 30, 60 min (and 120 min for [18F]2b) post injection, the rats were 
anesthetized and euthanized. The whole brain was quickly removed and dissected into segments 
consisting of brain stem, thalamus, striatum, hippocampus, cortex and cerebellum. The remainder of 
the brain was also collected to determine total brain uptake. At the same time, samples of blood, heart, 
lung, muscle, fat, pancreas, spleen, kidney, liver (and bone for [18F]2b) were removed and counted in a 
Beckman Gamma 8000 well counter with a standard dilution of the injectate. Tissues were weighed, 
and the percent injected dose (%ID)/gram for each tissue was calculated.  
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2.4. MicroPET Brain Imaging Studies of [11C]2a in Cynomolgus Macaque 
Following the initial evaluation in rats, the washout kinetics and ability of [11C]2a to cross the 
blood-brain barrier in a non-human primate (NHP) was determined on an adult male cynomolgus 
macaque (6−8 kg) using a microPET Focus 220 scanner (Concorde/CTI/Siemens Microsystems, 
Knoxville, TN). Before each scan (n = 2), the animal was fasted for 12 h and then initially anesthetized 
with ketamine (10 mg/kg) and glycopyrrolate (0.13 mg/kg) intramuscularly. Upon arrival at the 
scanner, the monkey was intubated, and a percutaneous catheter placed for tracer injection. The head 
was positioned supine in the adjustable head holder with the brain in the center of the field of view. 
Anesthesia was maintained at 0.75%−2.0% isoflurane/oxygen and the core temperature maintained at  
37 °C. A 10-min transmission scan was performed to confirm positioning; this was followed by a  
45-min transmission scan for attenuation correction. Subsequently, a 2-h dynamic emission scan was 
acquired after venous injection of 300−370 MBq of [11C]2a. 
3. Results and Discussions 
3.1. Chemistry 
Compounds 2a and 2b possess a methoxy and fluoroethoxy group, respectively, enabling 
radiolabeling through O-alkylation of the corresponding phenol precursor. However, to avoid 
undesired N-alkylation product, the acetyl protected Compound 4 was used as the precursor for the 
radiosyntheses. As shown in Scheme 1, the synthesis of 4 was accomplished by a two-step strategy 
starting from 2a following our previous procedure [17]. N-acetylation of 2a was achieved using acetyl 
chloride. Removing the O-methyl group of 3 with boron tribromide afforded the phenol Precursor 4, 
which was used in the radiosyntheses of 2a and 2b. Due to the reaction scale difference, the yields for 
certain reactions differ slightly from our previous report. 
3.2. Radiochemistry 
The radiosynthesis of [11C]2a was accomplished by a two-step approach. The reaction of the phenol 
Precursor 4 with [11C]CH3I was performed in DMF in the presence of NaOH [19–21], and the N-acetyl 
group of the 11C-labeled intermediate was removed by DBU following the literature procedure [22], as 
outlined in Scheme 2. [11C]2a was obtained in approximately 35%–45% overall radiochemical yield 
(RCY) after HPLC purification (n = 4). The radiochemical purity of [11C]2a was >99% and chemical 
purity was >95%. [11C]2a was identified by co-eluting with the solution of standard 2a. The entire 
synthetic procedure, including the production of [11C]CH3I, radiosynthesis, HPLC purification and 
formulation of the radiotracer for animal studies, was completed within 50–60 min. [11C]2a was 
obtained in a specific activity of >363 GBq/µmol at EOB (n = 4).  
The radiosynthesis of [18F]2b was achieved using a three-step reaction. The radioactive 
intermediate, [18F]fluoroethyltosylate ([18F]FEOTs), was first synthesized through a typical 
fluorination of the di-tosylate substrate [23–27]. Treatment of ethylene glycol ditosylate using 
[18F]fluoride, potassium carbonate and Kryptofix 222 gave [18F]FEOTs in good yield (60%–70%, 
decay corrected) after HPLC purification. The intermediate was reacted with the precursor, followed 
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by DBU hydrolysis to afford a sufficient dose of [18F]2b with the labeling yield of 55%–65% after 
HPLC purification (n = 4, decay corrected to EOB). The radiochemical purity of [18F]2b was >98%, 
and the chemical purity was >95%. [18F]2b was identified by co-eluting with the solution of standard 
2b. The entire synthetic procedure, including the drying of [18F]F−, the radiosynthesis, HPLC 
purification and formulation of the radiotracer for in vivo studies, was completed in 3 h. Radiotracer 
[18F]2b was obtained in a specific activity of >200 GBq/µmol (decay corrected to EOB, n = 4).  
Table 1. Biodistribution of [11C]2a and [18F]2b in male Sprague-Dawley rats (%ID/gram). 
Radioligand Organ 5 min 30 min 60 min 120 min 
[11C]2a 
blood 0.506 ± 0.040 0.369 ± 0.031 0.300 ± 0.015  
heart 0.758 ± 0.052 0.377 ± 0.046 0.245 ± 0.010  
lung 1.149 ± 0.058 0.740 ± 0.038 0.485 ± 0.036  
muscle 0.271 ± 0.005 0.325 ± 0.030 0.199 ± 0.016  
fat 0.155 ± 0.023 0.241 ± 0.042 0.293 ± 0.076  
pancreas 1.007 ± 0.262 0.506 ± 0.066 0.522 ± 0.036  
spleen 0.659 ± 0.049 0.400 ± 0.052 0.386 ± 0.027  
kidney 1.362 ± 0.054 0.807 ± 0.086 0.559 ± 0.053  
liver 2.198 ± 0.111 1.349 ± 0.116 1.116 ± 0.024  
brain 0.953 ± 0.115 0.287 ± 0.046 0.158 ± 0.013  
[18F]2b 
blood 0.553 ± 0.047 0.589 ± 0.016 0.606 ± 0.035 0.585 ± 0.046 
heart 0.757 ± 0.033 0.505 ± 0.015 0.466 ± 0.040 0.410 ± 0.030 
lung 0.833 ± 0.053 0.561 ± 0.021 0.491 ± 0.030 0.436 ± 0.018 
muscle 0.430 ± 0.031 0.451 ± 0.018 0.376 ± 0.019 0.315 ± 0.015 
fat 0.255 ± 0.037 0.425 ± 0.023 0.371 ± 0.067 0.293 ± 0.048 
pancreas 1.004 ± 0.147 0.546 ± 0.068 0.409 ± 0.029 0.330 ± 0.021 
spleen 0.672 ± 0.064 0.509 ± 0.022 0.446 ± 0.038 0.398 ± 0.019 
kidney 1.070 ± 0.058 0.988 ± 0.090 0.678 ± 0.032 0.659 ± 0.027 
liver 1.626 ± 0.221 0.847 ± 0.027 0.561 ± 0.028 0.467 ± 0.023 
bone 0.340 ± 0.027 0.309 ± 0.020 0.407 ± 0.043 0.644 ± 0.071 
brain 0.758 ± 0.013 0.465 ± 0.018 0.410 ± 0.030 0.359 ± 0.016 
3.3. Biodistribution in Rats 
The radioactivity distribution in various organs after the injection of [11C]2a and [18F]2b in rats is 
summarized in Table 1. Both radiotracers displayed homogeneous distribution in the brain regions as 
shown in Figure 2A,B. For [11C]2a, the total brain uptake (%ID/gram) of radioactivity at five, 30 and  
60 min post injection were 0.953 ± 0.115, 0.287 ± 0.046 and 0.158 ± 0.014 respectively; in the 
peripheral tissues, liver had the highest uptake among the tissues analyzed; the uptake (%ID/gram) in 
liver reached 2.198 ± 0.111 at 5 min and 1.116 ± 0.024 at 60 min. For [18F]2b, the total brain uptake 
(%ID/gram) at five, 30, 60 and 120 min was 0.758 ± 0.013, 0.465 ± 0.018, 0.410 ± 0.030 and  
0.359 ± 0.016, respectively; At 5 min post-injection, this compound also has a high liver uptake: 
(%ID/gram) of 1.626 ± 0.221. However, after 30 min, the kidney has retained the highest radioactivity 
of all tissues that were analyzed. The bone uptake (%ID/gram) was very stable and no defluorination 
was observed for [18F]2b. More importantly, the ex vivo rat biodistribution data revealed that both 
compounds readily crossed the BBB and entered the brain. Both tracers exhibit high initial brain 
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uptake and appropriate washout kinetics in the brain of normal rats. Rapid clearance of the 
radioactivity for both [11C]2a and [18F]2b was observed from brain, as well as other organs, such as 
lung, pancreas, spleen, kidney and liver. However, [11C]2a showed faster wash-out kinetics than 
[18F]2b, as shown in Figure 2. [11C]2a was chosen for subsequent microPET evaluation in an NHP. 
Figure 2. Regional radioactivity uptake in male Sprague Dawley (SD) rat brain (n = 4). 
(A) Regional brain uptake of [11C]2a; (B) regional brain uptake of [18F]2b. Cb, cerebellum; 
Ctx, cortex; Str, striatum; Thal, thalamus; Hippo, hippocampus. 
 
3.4. MicroPET Studies in NHP 
The representative summed images from zero to 120 min were co-registered with MRI images to 
accurately identify the regions of interest (Figure 3). The time-activity curve (TAC) revealed high 
initial uptake of [11C]2a in the brain, which peaked at 3 min post-injection; then, the radioactivity was 
quickly washed out from all brain regions. The summed image revealed a homogeneous distribution of 
radioactivity in the brain of the normal cynomolgus macaque. The microPET studies suggested that 
[11C]2a was able to cross the BBB and had a fast washout kinetics from the brain regions. The 
macaque used in the studies was a healthy young adult, and the distribution of the α-syn radioligand 
throughout the brain regions was homogeneous. Higher expression of α-syn protein in particular 
regions should not be observed in healthy subjects; thus, homogeneous distribution of the radioactivity 
in the macaque brain was expected. Nevertheless, PET studies of [11C]2a performed on an NHP model 
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bearing the over-expression of α-syn aggregation will directly determine the in vivo specificity of  
the radiotracer.  
Figure 3. In vivo microPET brain imaging studies of [11C]2a in cynomolgus macaque. (A) 
PET image (left), co-registered with MRI (middle), MRI image (right);  
(B) time-activity curves. SUV, standardized uptake value. 
 
4. Conclusions 
In summary, two α-syn ligands, [11C]2a and [18F]2b, were successfully radiosynthesized by  
O-alkylation of the desalkyl precursor. The biodistribution studies of [11C]2a and [18F]2b were 
conducted in male Sprague-Dawley rats and showed that both tracers were able to cross the BBB with 
high initial uptake. At 5 min post-injection, the uptake (%ID/gram) reached 0.953 ± 0.115 for [11C]2a 
and 0.758 ± 0.013 for [18F]2b. Both [11C]2a and [18F]2b displayed a homogeneous distribution 
throughout the brain of healthy adult male rats with rapid washout kinetics. In vivo microPET imaging 
in a healthy cynomolgus macaque confirmed that [11C]2a was able to enter the brain, had 
homogeneous distribution and rapid washout kinetics. Further structural optimization of [11C]2a and 
[18F]2b may lead to a highly specific radioligand for imaging α-syn aggregation in vivo.  
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